AL Amyloidosis: Connect Kidney and Cardiac Findings

Case reports · Visual teaching summary · October 3, 2026

Andrew Bland, MD, FACP, FAAP

Visual summary

Confirm the amyloid type before assigning prognosis or selecting disease-specific therapy.

Connect clone, protein and tissue injury. See the diagram description and full text below.
· Download full-size illustration (PNG) · Download Markdown · Read text version ·

Illustration updated October 18, 2026. Educational schematic. Imaging and microscopy panels are illustrations, not patient studies. Full teaching text and sources follow.

Diagram description

Connect clone, protein and tissue injury. Plasma-cell clone — Establish the hematologic process; Light-chain protein — Interpret complementary monoclonal tests; Kidney involvement — Protein loss and tissue evidence; Cardiac involvement — Structure, biomarkers and physiology. Confirm clone and amyloid type separately; follow organ and hematologic responses. The infographic uses anatomical illustrations and integrated labels; the complete teaching text and evidence are below.

Text version

Recognize the constellation

Heavy proteinuria, edema, declining kidney function, and unexplained cardiac findings should prompt consideration of systemic disease. AL amyloidosis can occur without the classic features of overt multiple myeloma.

Phenotype the urine protein

Compare total urine protein with albumin using compatible units and methods. Albumin-predominant proteinuria suggests glomerular injury; a nonalbumin component warrants investigation rather than an automatic light-chain diagnosis.

Check the monoclonal measurements

Use serum and urine immunofixation plus serum free light chains as indicated. For dFLC, subtract uninvolved from involved chain using the same units; 1 mg/dL equals 10 mg/L. Kidney dysfunction alters concentrations. A urine total-protein measurement does not tell you how much urinary light chain is present.

Confirm and type deposits

A monoclonal protein does not itself establish AL amyloidosis. Tissue confirmation and reliable amyloid typing are essential when required by the diagnostic pathway and clinical context.

Use measured staging inputs

Apply only the measured biomarkers and exact definitions required by a validated amyloid staging system. BNP cannot be substituted numerically for NT-proBNP. Do not call dFLC an underestimated floor merely because total proteinuria is heavy; establish the protein composition and tissue type.

Coordinate treatment

Hematology and organ specialists coordinate clone-directed treatment and supportive care. Fluid removal may be difficult when congestion coexists with limited cardiac reserve; reassess symptoms and perfusion.

Supporting evidence

Continue learning